Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 7/20 | 0.63 |
| ▸ | BRAF | P15056 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861962 | 1.00 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL12694504 | 1.00 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL5791330 | 0.98 | KDR (0.96) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4363892 | 0.94 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4543221 | 0.92 | KDR (0.85) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4543217 | 0.92 | KDR (0.85) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4371915 | 0.90 | KDR (0.83) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL5791918 | 0.89 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4366896 | 0.89 | KDR (1.00) | KDRLCKCSF1RIGF1RMET | |
| SCHEMBL4364745 | 0.89 | KDR (0.80) | KDRLCKCSF1RIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | claimed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | KDR 83/4885LCK 1957/4885CSF1R 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.